Device Trial Radar · NCT04195568
Evaluation of Safety and Effectiveness of Stryker Surpass Evolve™ Flow Diverter System
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
248
Actual
Start
Jul 7, 2020
Primary completion
Jul 14, 2025
Study completion Sep 13, 2028
Sponsor
- Lead sponsor
- Stryker NeurovascularPublic (SYK)
- Sponsor type
- Industry
- First posted
- Dec 12, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and effectiveness of the Surpass™ Evolve Flow Diverter System in the treatment of unruptured, wide-neck intracranial aneurysms measuring ≤ 12 mm and located on the ICA or its branches
Conditions
- Aneurysm, Intracranial
Interventions
Surpass Evolve Flow Diverter SystemDevice
The Surpass Evolve Flow Diverter System is indicated for the endovascular treatment of adults (age 18 or above) with unruptured saccular wide-neck or fusiform intracranial aneurysms ≤12 mm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Effectiveness EndpointTime frame: 12 months (± 3 months) post procedure
- Primary Safety EndpointTime frame: 12 Months (± 3 months) post procedure
Locations
37 sites in 3 countries. Site status is shown where the registry gives one.
DIGNITY HEALTH/ Barrow Neurological Institute
Phoenix, Arizona
St. Joseph's Hospital
Tucson, Arizona
University of California, Los Angeles
Los Angeles, California
34 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.